SAN DIEGO, March 3, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data analyzing the long-term outcomes of treating tardive dyskinesia (TD) with INGREZZA® (valbenazine) capsules in older (≥55 years) and elderly (≥65 years) patients from two studies (KINECT™ 3-extension and KINECT™ 4). These data (Poster #NR-36, Improvements Over Time with Long-Term Valbenazine in Older and Elderly Patients with Tardive Dyskinesia) are being presented at the American Association for Geriatric Psychiatry (AAGP) 2023 Annual Meeting from March 3–6 in New Orleans.
Read more at prnewswire.comProvided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.